Literature DB >> 10582095

Human immunodeficiency viruses in the developing world.

M Essex1.   

Abstract

AIDS has become a major burden in developing countries. At present, more than 90% of new HIV infections are emerging in Asia and Africa. Particularly ominous is the epidemic due to HIV-1 C in southern Africa, where about 25% of adults in several countries are infected. Although most of its spread apparently occurred during the 1990s, HIV-1 C currently accounts for one-half of the infections in the world. Both HIV-2, which is less virulent than HIV-1, and HIV-1 apparently spread to the human population from nonhuman African primates during the twentieth century. HIV-1 infection is usually lethal in the absence of antiretroviral therapy, but clinical disease occurs only after an induction period of several years. Some subtypes of HIV-1, such as C, E, and A, appear to be transmitted more efficiently than HIV-1 B, which is the major subtype in the United States and Europe. Molecular evolutionary changes that include receptor affinity, mediated by the env gene, and increased transcriptional activation, mediated by changes in the LTR and the tat gene, may account for some of the changes in transmission. Current therapies are prohibitively expensive for use in adults in most developing countries, although drugs for maternal-to-infant transmission are becoming accessible. A vaccine for HIV is desperately needed for the developing world.

Entities:  

Mesh:

Year:  1999        PMID: 10582095     DOI: 10.1016/s0065-3527(08)60343-7

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  34 in total

Review 1.  The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa.

Authors:  J M Bos; M J Postma
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine.

Authors:  Udaykumar Ranga; Raj Shankarappa; Nagadenahalli B Siddappa; Lakshmi Ramakrishna; Ramalingam Nagendran; Marthandan Mahalingam; Anita Mahadevan; Narayana Jayasuryan; Parthasarathy Satishchandra; Susarla K Shankar; Vinayaka R Prasad
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.

Authors:  Nannan Zhou; Beata Nowicka-Sans; Sharon Zhang; Li Fan; Jie Fang; Hua Fang; Yi-Fei Gong; Betsy Eggers; David R Langley; Tao Wang; John Kadow; Dennis Grasela; George J Hanna; Louis Alexander; Richard Colonno; Mark Krystal; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

5.  Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.

Authors:  Salerwe Mosebi; Lynn Morris; Heini W Dirr; Yasien Sayed
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

Review 6.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

7.  The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Authors:  Kevin K Ariën; Awet Abraha; Miguel E Quiñones-Mateu; Luc Kestens; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.

Authors:  M Sarah Hill; Autumn Ruiz; Erik Pacyniak; David M Pinson; Nathan Culley; Bonnie Yen; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

10.  Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.

Authors:  A Heredia; A Amoroso; C Davis; N Le; E Reardon; J K Dominique; E Klingebiel; R C Gallo; R R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.